tiprankstipranks
Trending News
More News >

InhaleRx Limited Secures R&D Tax Rebate to Bolster Financial Position

Story Highlights
InhaleRx Limited Secures R&D Tax Rebate to Bolster Financial Position

Don’t Miss TipRanks’ Half-Year Sale

An announcement from InhaleRx Limited ( (AU:IRX) ) is now available.

InhaleRx Limited has received a $402,000 rebate from its FY2024 Research and Development Tax Incentive claim, which will be used for working capital and partial repayment of a funding facility with Clendon Biotech Capital. Additionally, the company expects an extra $88,000 from an amended FY2023 tax return, further supporting its working capital. This financial boost aids InhaleRx in its continued development of drug-device products, potentially strengthening its market position and benefiting shareholders.

More about InhaleRx Limited

InhaleRx Limited is an Australian drug development company focused on creating unique medicinal drug-device products aimed at addressing unmet medical needs in pain management and mental health sectors. The company is pursuing U.S. FDA approval through rapid and cost-effective regulatory pathways, targeting conditions such as Breakthrough Cancer Pain and Panic Disorder, where current treatment options are limited.

Average Trading Volume: 308,866

Technical Sentiment Signal: Buy

Current Market Cap: A$8.54M

See more insights into IRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1